RCM Technologies Q2 revenue rises on engineering and health care growth
RCMT•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the employment services peer group is "buy"
- Wall Street's median 12-month price target for R C M Technologies Inc is $38.00, about 31.4% above its August 13 closing price of $28.92
- The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago
Segment drivers and outlook
- ENGINEERING SEGMENT GROWTH - Q2 revenue in engineering segment rose to $39.5 mln from $26.5 mln a year earlier
- SPECIALTY HEALTHCARE STRENGTH - Specialty healthcare revenue increased to $44.7 mln in Q2 from $42.8 mln a year earlier
- Company did not provide specific guidance or outlook for future quarters or the full year in press release
Q2 revenue and earnings rise
- Business solutions provider's Q2 revenue grew 20% yr/yr
- Adjusted EPS for Q2 rose 19% yr/yr
- Company attributed performance to growth in engineering and healthcare segments
Key details
| Metric | Beat/Miss |
|---|
